NexImmune (NEXI) Competitors $0.0001 0.00 (0.00%) As of 10/9/2025 11:34 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock NEXI vs. ATNFW, LBPSW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, CALA, and CELUWShould you be buying NexImmune stock or one of its competitors? The main competitors of NexImmune include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), Calithera Biosciences (CALA), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. NexImmune vs. Its Competitors 180 Life Sciences 4D pharma Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Calithera Biosciences Celularity 180 Life Sciences (NASDAQ:ATNFW) and NexImmune (NASDAQ:NEXI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability. Do insiders & institutionals hold more shares of ATNFW or NEXI? 9.9% of NexImmune shares are held by institutional investors. 14.9% of NexImmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is ATNFW or NEXI more profitable? 180 Life Sciences' return on equity of 0.00% beat NexImmune's return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A NexImmune N/A -534.32%-213.72% Which has stronger earnings & valuation, ATNFW or NEXI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ANexImmuneN/AN/A-$32.34M-$18.540.00 Does the media refer more to ATNFW or NEXI? In the previous week, 180 Life Sciences' average media sentiment score of 0.00 equaled NexImmune'saverage media sentiment score. Company Overall Sentiment 180 Life Sciences Neutral NexImmune Neutral Summary180 Life Sciences and NexImmune tied by winning 2 of the 4 factors compared between the two stocks. Get NexImmune News Delivered to You Automatically Sign up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEXI vs. The Competition Export to ExcelMetricNexImmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$1.03B$6.14B$10.65BDividend YieldN/A4.84%5.66%4.70%P/E Ratio0.001.2585.8427.65Price / SalesN/A30.97621.93138.22Price / CashN/A17.6438.3262.20Price / Book0.007.3613.066.79Net Income-$32.34M-$7.96M$3.30B$275.88M7 Day PerformanceN/A30.95%3.72%1.90%1 Month PerformanceN/A28.00%10.70%8.90%1 Year PerformanceN/A-6.57%84.94%36.28% NexImmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEXINexImmuneN/A$0.00flatN/A-100.0%$0.00N/A0.0070ATNFW180 Life SciencesN/A$0.08+0.1%N/A+572.5%$0.00N/A0.007Gap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAIMDWAinosN/A$0.19+37.0%N/A+442.2%$0.00$110.87K0.0040Positive NewsGap UpALVOWAlvotechN/A$1.52+26.6%N/A-50.5%$0.00$560.10M0.004Positive NewsGap UpHigh Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.02-22.8%N/A-38.4%$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.10+3.1%N/A+363.7%$0.00$39.19M0.0070Positive NewsBTMDWbioteN/A$0.01-2.1%N/AN/A$0.00$199.07M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.03-7.1%N/A-84.4%$0.00N/A0.008Negative NewsCALACalithera BiosciencesN/A$0.00flatN/A-90.0%$0.00N/A0.0060CELUWCelularityN/A$0.04-12.0%N/AN/A$0.00$44.59M0.00220Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies 180 Life Sciences Competitors 4D pharma Competitors Ainos Competitors Alvotech Competitors Atlantic Coastal Acquisition Corp. II Competitors Biofrontera Competitors biote Competitors BriaCell Therapeutics Competitors Calithera Biosciences Competitors Celularity Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEXI) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredElon callingElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | SponsoredNvidia and AMD just surged. But this setup was already winning.Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
